Alterity Therapeutics (ATHE) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeonaBio (LONA) has outperformed Alterity Therapeutics (ATHE) over the past year, gaining 46.7% versus a loss of 28.8%. Over five years, ATHE leads with a -76.6% price change compared with -94.0% for LONA. Alterity Therapeutics is the larger company by market cap ($56.7 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | LONA |
|---|---|---|
| Share price | $3.12 | $5.75 |
| Market cap | $56.72M | $54.17M |
| 1-day change | +1.47% | 0.00% |
| YTD return | -0.32% | -24.04% |
| 1-year return | -28.77% | +46.68% |
| 5-year return | -76.56% | -93.99% |
| EPS (TTM) | $-0.90 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.89 | $14.21 |
| 52-week low | $2.66 | $2.21 |
| Distance from 52-week high | -47.11% | -59.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +325.36% | +201.39% |
| Average volume | 16.47K | 185.45K |
| Shares outstanding | 18.21M | 9.42M |
| Employees | 11 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed ATHE by 75.5 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
ATHE vs LONA FAQ
Which is bigger, Alterity Therapeutics or LeonaBio?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $56.72M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, ATHE or LONA?
LONA returned +46.68% over the past 12 months, compared with -28.77% for ATHE (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and LeonaBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alterity Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for LeonaBio.